EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Folate Receptor Alpha—A Secret Weapon in Ovarian Cancer Treatment?

Karol Bukowski iD, Aneta Rogalska iD, Agnieszka Marczak iD

International Journal of Molecular Sciences · 06.11.2024 · 25 (22) · 11927

DOI: 10.3390/ijms252211927 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.11.2024. Verfasst von Karol Bukowski und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska Stre…. Hauptthemen laut MEDLINE: Folate Receptor 1, Ovarian Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epithelial ovarian cancer (EOC) is the most lethal gynecological malignancy worldwide. Due to its nonspecific symptoms and unreliable screening tools, EOC is not diagnosed at an early stage in most cases. Unfortunately, despite achieving initial remission after debulking surgery and platinum-based chemotherapy, most patients experience the recurrence of the disease. The limited therapy approaches have encouraged scientists to search for new detection and therapeutic strategies. In this review, we discuss the role of folate receptor alpha (FRα) in EOC development and its potential application as a biomarker and molecular target in designing new EOC screening and treatment methods. We summarize the mechanisms of the action of various therapeutic strategies based on FRα, including MABs (monoclonal antibodies), ADCs (antibody–drug conjugates), FDCs (folate–drug conjugates), SMDCs (small molecule–drug conjugates), vaccines, and CAR-T (chimeric antigen receptor T) cells, and present the most significant clinical trials of some FRα-based drugs. Furthermore, we discuss the pros and cons of different FR-based therapies, highlighting mirvetuximab soravtansine (MIRV) as the currently most promising EOC-targeting drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Folate Receptor 1Ovarian NeoplasmsHumansFemaleCarcinoma, Ovarian EpithelialBiomarkers, TumorImmunoconjugatesAnimalsMolecular Targeted TherapyAntibodies, MonoclonalMaytansineAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

MIRVantibody–drug conjugatesbiomarkerchimeric antigen receptor Tepithelial ovarian cancerfolate–drug conjugatesmonoclonal antibodiessmall molecule–drug conjugatesvaccinesvintafolide

Substanzen

Folate Receptor 1mirvetuximab soravtansineBiomarkers, TumorImmunoconjugatesFOLR1 protein, humanAntibodies, MonoclonalMaytansineAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical Biophysics, Institute of Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 141/143 Pomorska Street, 90-236 Lodz, Poland.

ORCID-Profile: Karol Bukowski, Aneta Rogalska, Agnieszka Marczak

Zitieren

APA

Bukowski, K., Rogalska, A., & Marczak, A. (2024). Folate Receptor Alpha—A Secret Weapon in Ovarian Cancer Treatment?. International Journal of Molecular Sciences, 25(22), 11927. https://doi.org/10.3390/ijms252211927

Vancouver

Bukowski K, Rogalska A, Marczak A. Folate Receptor Alpha—A Secret Weapon in Ovarian Cancer Treatment?. International Journal of Molecular Sciences. 2024;25(22):11927. doi:10.3390/ijms252211927

BibTeX
@article{Bukowski2024,
  author = {Bukowski, Karol and Rogalska, Aneta and Marczak, Agnieszka},
  title = {Folate Receptor Alpha—A Secret Weapon in Ovarian Cancer Treatment?},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {22},
  pages = {11927},
  doi = {10.3390/ijms252211927}
}
Kostenlos starten →